Safety and tolerability of topical trametinib in rosacea: Results from a phase I clinical trial
Abstract Purpose Overactivation of the mitogen activated kinase pathway has been associated with rosacea. We hypothesised that inhibitors of this pathway can be repurposed to alleviate rosacea symptoms. Methods In order to test this hypothesis, we designed a double‐blind, randomised, placebo‐control...
Main Authors: | Edward J. Wladis, Jacqueline Busingye, Leahruth K. Saavedra, Amy Murdico, Alejandro P. Adam |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-04-01
|
Series: | Skin Health and Disease |
Online Access: | https://doi.org/10.1002/ski2.346 |
Similar Items
-
SH2 domain‐containing protein tyrosine phosphatase‐2 is enriched in eyelid specimens of rosacea
by: Apoorv Chebolu, et al.
Published: (2023-02-01) -
Treatment-refractory cutaneous Rosai–Dorfman disease responsive to oral methotrexate and topical trametinib
by: Christopher J. Fay, BA, et al.
Published: (2023-09-01) -
New combined topical therapy for refractory rosacea
by: E. A. Smirnova, et al.
Published: (2018-12-01) -
Topical tranexamic acid improves the permeability barrier in rosacea
by: Shaomin Zhong, et al.
Published: (2015-06-01) -
Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
by: Walid Shalata, et al.
Published: (2023-02-01)